参考文献/References:
[1] SANCHI-GOMAR F,CARME P,ROMAN L,et al.Epidemiology of coronary heart disease and acute coronary syndrome[J].Ann Transl Med,2016,4(13):256-256.
[2] HAUSENLOY D J,YELLON D M.Myocardial ischemia-reperfusion injury:a neglected therapeutic target[J].J Clin Invest,2013,123(1):92-100.
[3] PRASAD A,STONE G W,HOLMES D R,et al.Reperfusion injury,microvascular dysfunction,and cardioprotection:the “dark side” of reperfusion[J].Circulation,2009,120(21):2105-2112.
[4] TOLDO S,MAURO A G,CUTTER Z S,et al.Inflammasome,pyroptosis,and cytokines in myocardial ischemia-reperfusion injury[J].Am J Physiol Heart Circ Physiol,2018,315(6):1553-1568.
[5] MCCARTHY C P,MULLINS K V,KERINS D M.The role of trimetazidine in cardiovascular disease:beyond an anti-anginal agent[J].Eur Heart J Cardiovasc Pharmacother,2016,2(4):266-272.
[6] ZHOU X,LI C,XV W,et al.Trimetazidine protects against smoking-induced left ventricular remodeling via attenuating oxidative stress,apoptosis,and inflammation[J].PLoS One,2012,7(7):e40424.
[7] XIAO J,WANG C,YAO J C,et al.Gasdermin D mediates the pathogenesis of neonatal-onset multisystem inflammatory disease in mice[J].PLoS Biol,2018,16(11):e3000047.
[8] 王星星,宋虎,杜晨阳,等.细胞焦亡的研究进展[J].天津医药,2018,46(11):1252-1256.
[9] ChENG J,WU Q,LV R,et al.MicroRNA-449a inhibition protects H9C2 cells against hypoxia/reoxygenation-induced injury by targeting the Notch-1 signaling pathway[J].Cell Physiol Biochem,2018,46(6):2587-2600.
[10] WEI J,XV H,SHI L,et al.Trimetazidine protects cardiomyocytes against hypoxia-induced injury through ameliorates calcium homeostasis[J].Chem Biol Interact,2015,236(3):47-56.
[11] 王紫监,张立民,赵自刚,等.心肌缺血再灌注损伤研究进展[J].中国老年学杂志,2018,38(6):1532-1535.
[12] MARCHANT D J,BOYD J H,LIN D C,et al.Inflammation in myocardial diseases[J].Circ Res,2012,110(1):126-144.
[13] ARSLAN F,DE KLEIJN D P,PASTERKAMP G.Innate immune signaling in cardiac ischemia[J].Nat Rev Cardiol,2011,8(5):292-300.
[14] TIMMERS L,PASTERKAMP G,DE HOOG V C,et al.The innate immune response in reperfused myocardium[J].Cardiovasc Res,2012,94(2):276-283.
[15] CHEN X,HE W T,HU L,et al.Pyroptosis is driven by non-selective gasdermin-D pore and its morphology is different from MLKL channel-mediated necroptosis[J].Cell Res,2016,26(9):1007-1020.
[16] NAZIR S,GADI I,AL-DABET M M,et al.Cytoprotective activated protein C averts Nlrp3 inflammasome-induced ischemia-reperfusion injury via mTORC1 inhibition[J].Blood,2017,130(24):2664-2677.
[17] TAKAHASHI M.NLRP3 inflammasome as a novel player in myocardial infarction[J].Int Heart J,2014,55(2):101-105.
[18] GRUNDMANN S,BODE C,MOSER M.Inflammasome activation in reperfusion injury:friendly fire on myocardial infarction[J].Circulation,2011,123(6):574-576.
[19] IKEDA U,IKEDA M,KANO S,et al.Neutrophil adherence to rat cardiac myocyte by proinflammatory cytokines[J].J Cardiovasc Pharmacol,1994,23(4):647-652.
[20] QIU Z,LEI S,ZHAO B,et al.NLRP3 inflammasome activation-mediated pyroptosis aggravates myocardial ischemia/reperfusion injury in diabetic Rats[J].Oxid Med Cell Longev,2017,2017:1-17.
[21] 毕莹,刘新林,刘小伟,等.曲美他嗪对急性前壁心肌梗死心肌缺血再灌注损伤的保护作用[J].武警医学,2017,22(10):988-991.
[22] CHEN J,LAI J,YANG L,et al.Trimetazidine prevents macrophage-mediated septic myocardial dysfunction via activation of the histone deacetylase sirtuin 1[J].Br J Pharmacol,2016,173(3):545-561.
[23] ENTURK T,AVUN S,AVCI B,et al.Effective inhibition of cardiomyocyte apoptosis through the combination of trimetazidine and N-acetylcysteine in a rat model of myocardial ischemia and reperfusion injury[J].Atherosclerosis,2014,237(2):760-766.
[24] 朱雪梅.曲美他嗪对急性心肌缺血再灌注损伤大鼠的治疗效果及对Bcl-2、Caspase-3蛋白表达的影响[J].心脑血管病防治,2018,18(1):11-14.
[25] 熊果,马康华.曲美他嗪预处理对缺血/再灌注大鼠心肌细胞凋亡的抑制及机制研究[J].天津医科大学学报,2018,24(2):116-121.
[26] 文冰,韩辉,焦周阳,等.曲美他嗪抗大鼠心肌缺血再灌注损伤中炎性反应的研究[J].中华实验外科杂志,2014,31(3):597-599.
[27] WU S,CHANG G,GAO L,et al.Trimetazidine protects against myocardial ischemia/reperfusion injury by inhibiting excessive autophagy[J].J Mol Med (Berl),2018,96(8):791-806.
[28] 龙玉莹,葛华,王月,等.盐酸曲美他嗪调控自噬对大鼠心肌缺血再灌注损伤的保护作用[J].中国医科大学学报,2017,46(7):656-659.